If you’ve been following innovation in drug development, you’ve likely heard of "organs-on-chips"—tiny devices that replicate human organs on a micro level. What used to sound like science fiction is now a fast-moving reality, and according to the latest report by Roots Analysis, organs-on-chips market is set to grow to a whopping USD 944 million by 2035.

The biggest reason? A strong global push to move away from animal testing.

“There's a real shift happening,” says a lead analyst at Roots Analysis. “Drug companies and researchers are increasingly looking for more human-relevant testing platforms, and these chips are stepping up to the plate.”

Organs-on-chips aren’t just cool tech. They’re changing how we understand drug responses—by mimicking how real human organs behave. Whether it’s a lung, liver, or even a multi-organ system that traces how a drug travels through the body, these chips are making testing faster, more ethical, and—critically—more accurate.

The report points out that organ-based models currently make up the bulk of the market. But it’s the disease-specific and multi-organ systems that are seeing the fastest growth. Researchers love that these chips don’t just simulate healthy organs—they also model diseases. That opens the door to far better early-stage testing and even personalized therapies down the road.

Still, this isn’t a silver bullet just yet. The tech is mostly used in preclinical work, and getting regulatory approval based on chip data is still a challenge. Plus, manufacturing isn’t cheap—at least not right now.

But even with those hurdles, momentum is building. Several companies are already leading the charge—names like Emulate, Mimetas, CN Bio, and Hesperos are pushing boundaries. And the applications go beyond pharma. The cosmetics industry, for example, is turning to organs-on-chips as a solution to test products without animals—a big plus in an industry facing tighter regulations.

North America is ahead in adoption, with Europe and Asia-Pacific close behind. And with more partnerships and funding coming in from both private and public sectors, the ecosystem around this tech is only going to grow stronger.

This isn't just a story about market numbers—though the numbers are impressive. It’s about where biomedical innovation is headed: more ethical, more precise, and more human-focused.

Read more-
Link- https://www.rootsanalysis.com/reports/organ-on-a-chip-market.html